PD-1 and PD-L1 Inhibitors Competitive landscape report 2022 by DelveInsight

PD-1 and PD-L1 Inhibitors Competitive landscape report 2022 by DelveInsight

“PD-1 and PD-L1 Inhibitors Competitive landscape”
PD-1 and PD-L1 Inhibitors pipeline constitutes 180+ key companies continuously working towards developing 200+ PD-1 and PD-L1 Inhibitors treatment therapies, analyzes DelveInsight

Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune responses and promoting self-tolerance through modulating the activity of T-cells, activating apoptosis of antigen-specific T cells and inhibiting apoptosis of regulatory T cells. Programmed Cell Death Ligand 1 (PD-L1) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response, it can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion and induce apoptosis. PD-L1 also plays an important role in various malignancies where it can attenuate the host immune response to tumor cells.

 

DelveInsights, “PD-1 and PD-L1 Inhibitors Competitive landscape, 2022” report provides comprehensive insights about 180+ companies and PD-1 and PD-L1 Inhibitors drugs in PD-1 and PD-L1 Inhibitors inhibitors Competitive landscape. It covers the therapeutics assessment by product type,stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To know more about the PD-1 and PD-L1 Inhibitors Pipeline report, click here: PD-1 and PD-L1 Inhibitors Competitive landscape

 

Key Takeaways from the PD-1 and PD-L1 Inhibitors Competitive landscape report:

  • Leading PD-1 and PD-L1 Inhibitors Companies working in the market are Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics and Others.
  • Key PD-1 and PD-L1 Inhibitors therapies in various stages of development include Keytruda, Tislelizumab, Geptanolimab, TECENTRIQ, Envafolimab, Durvalumab, CA 170, FAZ 053, SG 12473, LP 002 and Others.
  • In September 2022, Merck announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received four new approvals from Japan’s Ministry of Health, Labor and Welfare.

 

DelveInsight’s PD-1 and PD-L1 Inhibitors Report covers around 200+ products under different phases of clinical development like:

  • Assessment by PD-1 and PD-L1 Inhibitors Product Type
  • Assessment by Stage and Product Type of PD-1 and PD-L1 Inhibitors
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration of PD-1 and PD-L1 Inhibitors
  • Assessment by PD-1 and PD-L1 Inhibitors Molecule Type
  • Assessment by Stage and Molecule Type of PD-1 and PD-L1 Inhibitors

 

Emerging PD-1 and PD-L1 Inhibitors Drugs Under Different Phases of Clinical Development Include:

Some of the PD-1 and PD-L1 Inhibitors therapies are TECENTRIQ, Envafolimab and Many Others.

 

Further PD-1 and PD-L1 Inhibitors product details are provided in the report. Download the PD-1 and PD-L1 Inhibitors Pipeline report to learn more about the emerging PD-1 and PD-L1 Inhibitors therapies at: PD-1 and PD-L1 Inhibitors treatment pipeline 

 

Key companies in the PD-1 and PD-L1 Inhibitors Therapeutics Market:

Some of the PD-1 and PD-L1 Inhibitors Companies working in the market are Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics and Others.

 

Request for Sample PDF Report to know in detail about the recent developments and advancements in PD-1 and PD-L1 Inhibitors clinical trials – Phases of PD-1 and PD-L1 Inhibitors Drugs in Pipeline

 

Table of Content (TOC)

1. PD-1 and PD-L1 Inhibitors Pipeline Report Introduction

2. PD-1 and PD-L1 Inhibitors Pipeline Report Executive Summary

3. PD-1 and PD-L1 Inhibitors Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. PD-1 and PD-L1 Inhibitors Clinical Trial Therapeutics

6. PD-1 and PD-L1 Inhibitors Pipeline: Late Stage Products (Pre-registration)

7. PD-1 and PD-L1 Inhibitors Pipeline: Late Stage Products (Phase III)

8. PD-1 and PD-L1 Inhibitors Pipeline: Mid Stage Products (Phase II)

9. PD-1 and PD-L1 Inhibitors Pipeline: Early Stage Products (Phase I)

10. PD-1 and PD-L1 Inhibitors Pipeline Therapeutic Assessment

11. Inactive Products in the PD-1 and PD-L1 Inhibitors Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key PD-1 and PD-L1 Inhibitors Companies

14. Key Products in the PD-1 and PD-L1 Inhibitors Pipeline

15. Unmet Needs

16. PD-1 and PD-L1 Inhibitors Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

 

Download Sample PDF Report to know more about @ https://www.delveinsight.com/sample-request/pd-1-and-pd-l1-inhibitors-competitive-landscape

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape